August 27, 2026 | AI, AI pharma, AI tools, Compliant AI, Impetus Digital, QIP, Quality improvement programs, artificial intelligence, compliance, insight gathering, medical education, pharma insights, pharma teams, pharma webinar, training programs, virtual tools
See how top-tier pharma teams use compliant AI tools and virtual QIPs to capture real-time market intelligence, confidence scores, and audience insights from live dashboards

AI sounds great in theory, but very few pharma teams know how to integrate it meaningfully into their programs without creating extra friction, compliance headaches, or overspending on tech hype. Join us for our upcoming webinar Oct 14, 22, & 27, where we move beyond the buzz to explore how agile Medical Affairs, Med Ed, and Commercial teams are leveraging practical, compliant AI tools and virtual workflows to transform passive audiences into active, high-retention collaborators.
From conversational AI peers and dynamic AI-driven presentations to virtual Quality Improvement Programs (QIPs), discover how top pharma companies are boosting knowledge retention by 4x and capturing real-time market intelligence without enterprise price tags or operational complexity. The future isn’t about adopting AI for the sake of it; it’s about choosing the right tools to elevate your engagement strategies.
Real Client Case Studies: Explore actual workflows and outcomes where top pharma brands successfully deployed AI across diverse programs.
A Showcase of Next-Gen Tools: Get a firsthand look at dynamic AI presenters, interactive avatars, virtual QIP environments, and more in action.
The Business Case & ROI: Discover how to achieve 4x higher retention and maximum impact while keeping project budgets surprisingly manageable.
Frictionless & Safe Implementation: Learn the rigorous training guardrails that guarantee pharma compliance, audit readiness, and zero open-web risk.
Creative Use Cases & Best Practices: Uncover actionable strategies and tips to integrate AI across Med Ed, Medical Affairs, and Commercial launches.
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
In recent years, social media has evolved into an essential part of Pharma operations, for better or worse.
Lucy Jung, CEO & Founder of Charco Neurotech, shares how meeting members of the Parkinson’s community catalyzed the founding of Charco and how #innovative medical devices and software can improve…
Dr. Joshua Liu, Co-founder & CEO of SeamlessMD, explores how technology and “Digital Care Journeys” can help hospitals reduce the surgical backlog for high-volume procedures like hip and knee replacements,…
Virtual engagement experts helping life science companies have ongoing conversations with their customers through our best-in-class online collaboration tools. Best-In-Class CollaborationTechnology Impetus Digital provides two turn-key software solutions through the Impetus…
Lucy Jung, CEO & Founder of Charco Neurotech, shares how meeting members of the Parkinson’s community catalyzed the founding of Charco and how #innovative medical devices and software can improve…
About the AwardToronto, ON, December 15, 2022 — PM360, a leading trade magazine for marketing decision-makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named Impetus Digital’s Virtual…
Dr. Ittai Dayan, Co-founder & CEO of Rhino Health, shares how his company is transforming the way healthcare AI solutions are created, adopted and measured. He will also explore how…
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program.
Tip #8 – Do you make sure to have a host for all your virtual events? Check our top 10 tips to increase engagement during virtual events: https://www.impetusdigital.com/2021/03/25/top-10-tips-to-increase-engagement-during-virtual-events/
Savva Kerdemelidis, Founder & CEO of Crowd Funded Cures, explores the concepts of interventional pharmacoeconomics and pay-for-success contracts to fund new uses for off-patent drugs and other unmonopolizable therapies.
